FIG4

Viralgen Vector Core and Elpida Therapeutics partner to manufacture gene therapy medicines for anticipated Spastic Paraplegia 50 (SPG50) and Charcot-Marie-Tooth disease type 4J (CMT4J) clinical trials

Retrieved on: 
Thursday, September 28, 2023
Epilepsy, Partnership, FIG4, Hypotonia, Quality of life, AP4M1, Cell, CMT, AAV, Patient, Intellectual, SAN, Microcephaly, Charcot–Marie–Tooth disease, Safety, Membrane, Disease, Pharmaceutical industry, Vaccine

SAN DIEGO, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Viralgen Vector Core (Viralgen) and Elpida Therapeutics (Elpida Tx) have partnered to manufacture gene therapies for use in clinical trials sponsored by Elpida Tx involving patients living with SPG50 or CMT4J.

Key Points: 
  • SAN DIEGO, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Viralgen Vector Core (Viralgen) and Elpida Therapeutics (Elpida Tx) have partnered to manufacture gene therapies for use in clinical trials sponsored by Elpida Tx involving patients living with SPG50 or CMT4J.
  • It is anticipated that these trials will take place at various sites in North America and Europe and will explore potential safety and efficacy of the new treatments to be manufactured, as well as potential quality of life improvements.
  • The same CMT4J genotype can present symptoms ranging from mild clinical signs to severe disability.2
    The partnership between Viralgen and Elpida Tx is expected to enable the efficient manufacture of the adeno-associated vector serotype 9 (AAV9) based therapies for use in Elpida Tx's anticipated multi-site clinical trials.
  • We feel so grateful and honored to be working with such an incredible partner."